Showing results (11-20 of 38) with videos related to
Sort By:
Pageof 4
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 16, 2012
CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft modelScott S Tykodi, Shoko Satoh, Janise D Deming, et al.Cancer Immunology, Immunotherapy : CII|June 14, 2012
Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)Richard Harrop, Peter Treasure, Jackie de Belin, et al.Cancer Immunology, Immunotherapy : CII|November 29, 2005
Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediatedRichard Harrop, Matthew G Ryan, Kevin A Myers, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 6, 2008
Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trialRobert J Amato, Noel Drury, Stuart Naylor, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trialRobert J Amato, William Shingler, Stuart Naylor, et al.Lung Cancer (Amsterdam, Netherlands)|April 14, 2012
Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesotheliomaSaly Al-Taei, Josephine Salimu, Jason F Lester, et al.Oncoimmunology|December 8, 2018
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trialJason F Lester, Angela C Casbard, Saly Al-Taei, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 4, 2009
Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alphaRobert E Hawkins, Catriona Macdermott, Alaaeldin Shablak, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 30, 2009
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trialRobert J Amato, William Shingler, Madusha Goonewardena, et al.Cancer Immunology, Immunotherapy : CII|December 7, 2007
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responsesRichard Harrop, Noel Drury, William Shingler, et al.Pageof 4